Abstract:
Objective:To study the relationship of serum visfatin levels and acute coronary syndrome(ACS) and the role of serum visfatin in vulnerable plaques.
Methods:The serum levels of visfatin and matrix metalloproteinase-9(MMP-9) in 40 cases with ACS,22 cases with stable angina pectoris(SAP) and 26 control cases were measured by ELISA,and the correlation between visfatin and MMP-9 was evaluated.
Results:The levels of visfatin and MMP-9 in cases with ACS were significantly higher than those in SAP and control groups(
P<0.01). Significant positive correlation of visfatin and MMP-9 in patients with ACS were found(
P<0.01).
Conclusions:The serum levels of visfatin and ACS exist correlation. Visfatin may act as the biomarkers of vulnerable plaques and be applied in the early prevention and management of ACS.